North East and North Cumbria
ICS Formulary
 
back
2 Cardiovascular system
02-12 Lipid-regulating drugs

Alirocumab
Formulary
  • Only approved for use in accordance with NICE guidance.
Link  NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

Red View adult BNF  View SPC online  View childrens BNF  HCD
Evolocumab
Formulary
  • Approved for use in accordance with NICE guidance for treating primary hypercholesterolaemia.
  • Approved for the treatment of homozygous familial hypercholesterolaemia in line with NHS England Commissioning policy.
Link  NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

Red View adult BNF  View SPC online  View childrens BNF  HCD
Icosapent ethyl Vazkepa®
Formulary
  • 998mg capsules
  • Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are taking statins, but only if they have:
    • established cardiovascular disease (secondary prevention), defined as a history of any of the following:
      • acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
      • coronary or other arterial revascularisation procedures
      • coronary heart disease
      • ischaemic stroke
      • peripheral arterial disease, and
    • low-density lipoprotein cholesterol (LDL‑C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre
Link  NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides

Green plus View adult BNF  View SPC online  View childrens BNF
Inclisiran Leqvio®
Formulary

  • 284mg/1.5ml solution for injection pre-filled syringes

    • Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults in line with NICE. 
Link  NICE TA 733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia

Green View adult BNF  View SPC online  View childrens BNF
Omega-3 Fatty Acid Compounds (excluding icosapent ethyl [Vazkepa®])
Non Formulary
  • Omega-3 fatty acid compounds are classified as BLACK - not approved.

Black View adult BNF  View SPC online  View childrens BNF